Status:

COMPLETED

Non-Interventional, Postmarketing Surveillance Study of Nusinersen Sodium Injection

Lead Sponsor:

Biogen

Conditions:

Muscular Atrophy, Spinal

Eligibility:

All Genders

Brief Summary

The primary objective of this study is to evaluate the safety of nusinersen sodium injection in the postmarketing setting in China.The secondary objectives are to collect data on the efficacy and the ...

Eligibility Criteria

Inclusion

  • Key
  • Ability of the participant or his/her legally authorized representative (e.g., parent or legal guardian), as appropriate and applicable, to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information in accordance with national and local subject privacy regulations.
  • The decision to newly prescribe nusinersen sodium injection according to the local marketing authorization, including documentation of 5q SMA diagnosis, has been made by the Investigator and agreed to by the participant (or legally authorized representative)
  • Key

Exclusion

  • Hypersensitivity to the active substance or any of the excipients of nusinersen sodium injection.
  • Current or past administration of nusinersen sodium injection, in either a commercial or a clinical study setting.
  • Other unspecified reasons that, in the opinion of the Investigator or the Sponsor, make the participant unsuitable for enrollment.
  • NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Key Trial Info

Start Date :

November 18 2020

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

November 21 2023

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT04419233

Start Date

November 18 2020

End Date

November 21 2023

Last Update

December 7 2023

Active Locations (9)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (9 locations)

1

Research Site

Xicheng, Beijing Municipality, China, 100045

2

Research Site

Fuzhou, Fujian, China, UNK

3

Research Site

Guangzhou, Guangdong, China, UNK

4

Research Site

Suzhou, Jiangsu, China, UNK